Skip to main content

Table 4 Percentage and dosage of concomitant drug use

From: Safety and efficacy of infliximab in the treatment of refractory uveoretinitis in Behçet’s disease: a large-scale, long-term postmarketing surveillance in Japan

 

Day 0

(n = 656)

Day 180

(n = 624)

Day 365

(n = 597)

Day 545

(n = 565)

Day 730

(n = 544)

Cyclosporine

n (rate)

178 (27.1)

121 (19.4)

112 (18.8)

103 (18.2)

99 (18.2)

 dose, mg/day

150.00 (100.00, 200.00)

100.00 (100.00, 150.00)

100.00 (75.00, 150.00)

100.00 (75.00, 150.00)

100.00 (75.00, 150.00)

Oral glucocorticoids

n (rate)

154 (23.5)

109 (17.5)

100 (16.8)

95 (16.8)

89 (16.4)

 dose, mg/day

10.00 (7.50, 20.00)

6.50 (5.00, 10.00)

5.00 (4.00, 10.00)

5.00 (5.00, 10.00)

5.00 (5.00, 10.00)

Colchicine

n (rate)

271 (41.3)

202 (32.4)

186 (31.2)

168 (29.7)

155 (28.5)

 dose, mg/day

1.00 (1.00, 1.00)

1.00 (0.50, 1.00)

1.00 (0.50, 1.00)

1.00 (0.50, 1.00)

1.00 (0.50, 1.00)

  1. Data are number (percentage) or median (1st quartile, 3rd quartile)